Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan and Capecitabine in Locally Advanced Rectal Cancer
NCT06210971Phase 2Active, not recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in rectal cancer, sponsored by The Fourth Hospital of Hebei Medical University. Started Feb 2024; status: active, not recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06210971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210971.